The SEM Scanner from BBI has received a Medtech Innovation Briefing (MIB), as part of the National Institute for Health and Care Excellence (NICE) advice. The SEM Scanner objectively alerts clinicians to specific anatomical areas of a patient’s body at increased risk for developing pressure damage, meaning patient risk assessments are performed before visible damage manifests at the skin surface – a world and clinical first.
In order to support NHS and social care staff who are considering using new medical devices, an MIB includes a description of the technology, how it is used, and its potential in the healthcare pathway. The briefing for the SEM Scanner also includes a review of published evidence and the likely costs of using the technology.
BBI CEO, Martin Burns, says: "Where we have seen our SEM Scanner in use, the results have been dramatic. This briefing will help avoid the need for organisations to produce similar information locally, saving staff time and resources.
"When you consider that the average prevention cost of using the SEM Scanner works out at just £1.50 per patient per day, we believe that we have game-changer technology available now in the UK.”
The SEM Scanner received European CE Mark approval in 2014, Health Canada clearance in 2016 and the US Food and Drug Administration (FDA) granted marketing authorisation in December 2018 under its De Novo review process for novel low-to moderate-risk devices that are not substantially equivalent to an already legally marketed device.